Lease liabilities – Laboratory equipment Lease finance obligations – Laboratory equipment Lease Financing Obligations, Equipment [Member] This member stands for lease finance obligations, equipment. Other tax credits Other Current Tax Credits Receivables The amount of other current tax credits receivables. Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [line items] Interest on financial liabilities Interest expense Number of filing and approval of a biologic license application Number Of Filing And Approval Of A Biologic License Application Number of filing and approval of a biologic license application Acquisition of property and equipment, net Purchase of property, plant and equipment, classified as investing activities Receipts from option agreement Receipts From Option Agreement The cash inflow from option agreement. Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Entity File Number Entity File Number Impairment of intangible assets Impairment of intangible assets Impairment Impairment loss recognised in profit or loss, intangible assets other than goodwill BSA 2017 BSA 2017 [Member] This member stands for BSA 2017. State guaranteed loans State Guaranteed Loans [Member] State Guaranteed Loans Deferred tax income / (loss) Deferred tax expense (income) Disclosure of detailed information about intangible assets Disclosure of detailed information about intangible assets [text block] Defined contribution plan, contribution percentage by employer Defined Contribution Plan Contribution Percentage By Employer The contribution percentage by employer pursuant to the defined contribution plan. Allocation of prior period loss Increase (decrease) through appropriation of retained earnings, equity Defined contribution plan, contribution percentage by employee Defined Contribution Plan Contribution Percentage By Employee The contribution percentage by employee pursuant to the defined contribution plan. 2028 Later than two years and not later than three years [member] Allowance for retirement defined benefit Retirement Defined Benefit [Member] This member stands for retirement defined benefit. Others differences Other tax effects for reconciliation between accounting profit and tax expense (income) Entity Addresses [Table] Entity Addresses [Table] Disclosure of financial liabilities per maturity Disclosure Of Financial Liabilities Per Maturity [Table Text Block] The disclosure of financial liabilities per maturity. 2018 Avdoralimab AstraZeneca Agreement 2018 Avdoralimab AstraZeneca Agreement [Member] 2018 Avdoralimab AstraZeneca Agreement Net financial income (loss) Finance income (cost) Increase capital, net (in shares) Increase Capital, Net (In Shares) The increase (decrease) in the number of shares issued resulting from the new shares issued during period. BSA 2023-1 BSA 2023-1 [Member] BSA 2023-1 Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) Exercised during the period Number of other equity instruments exercised or vested in share-based payment arrangement Subtotal (excluding RoU) Property Plant And Equipment Excluding Right Of Use Assets [Member] Property Plant And Equipment Excluding Right Of Use Assets Statement of comprehensive income [abstract] Statement of comprehensive income [abstract] Statement of changes in equity [line items] Statement of changes in equity [line items] Basic income (loss) per share from continuing operations (in EUR per share) Basic earnings (loss) per share from continuing operations of which Takeda agreement 2023 Agreement With Takeda [Member] Agreement With Takeda Service and actualization costs Increase In Net Defined Benefit Liability (Asset) Resulting From Current Service And Actualization Costs Increase In Net Defined Benefit Liability (Asset) Resulting From Current Service And Actualization Costs Grant and other tax credit Income from government grants Unrealized gains on financials assets Unrealized Gains On Financial Assets The amount of unrealized gains on financial assets. Provision for attendance fees Provision For Attendance Fees The amount of provision for attendance fees. Net income (loss) Retained earnings, profit (loss) for reporting period Expired during the period Number of other equity instruments expired in share-based payment arrangement Exercise price (in EUR per share) Exercise Price Other Equity Instruments Granted The exercise price of other equity instruments granted. In progress Intangible assets under development [member] Exercise of share warrants Exercise Of Share Warrants [Member] Exercise Of Share Warrants Summary of changes in working capital [abstract] Summary Of Changes In Working Capital [Abstract] Summary Of Changes In Working Capital Non-cancellable off-balance sheet purchase commitments Non Cancellable Off Balance Sheet Purchased Commitments Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date. Research tax credit Non-Current Research Tax Credit The amount of non-current research tax credit. Fair value through profit or loss Financial assets at fair value through profit or loss, category [member] Deferred tax liabilities / Deferred revenue Deferred Revenue [Member] This member stands for deferred revenue. Statement of financial position [abstract] Statement of financial position [abstract] Other income and (expenses), net Other operating income (expense) Operating expenses Disclosure of expenses [text block] Cover [Abstract] Cover [Abstract] BSA BSA [Member] This member stands for BSA. Maximum Maximum [Member] Initial payment Revenue From Contracts With Customers, Initial Payment The amount of initial payment pursuant to the agreement. Carry-back Carry-back The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to carry-back. Provisions and contingent liabilities Description of accounting policy for provisions [text block] Percentage of over performance Percentage Of Over Performance Percentage Of Over Performance Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Disclosure of schedule for the contractual flows of financial liabilities Disclosure Of Financial Liabilities, Classified [Table Text Block] The disclosure of financial liabilities, classified. Deferred tax assets / Provision for defined benefit obligation Provision for defined benefit obligation [Member] Provision for defined benefit obligation AGA Bonus 2020-1 AGA Bonus 2020 -1 [Member] AGA Bonus 2020 -1 Free performances shares plans, performance (in percents) Free Performances Shares Plans, Performance Percentage Free Performances Shares Plans, Performance Percentage Entity Shell Company Entity Shell Company Share premium Share premium Other purchases and external expenses Other Purchases And External Expenses The amount of other purchases and external expenses. AGA employees 2024-1 AGA Employees 2024-1 [Member] AGA Employees 2024-1 Total Contract liabilities [abstract] Classes of liabilities Classes of liabilities [domain] Non-current financial assets Non-current Financial Assets [Member] This member stands for non-current financial assets. Actuarial (loss) gain Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income Licensing agreement, maximum milestone payment Licensing Agreement, Maximum Milestone Payment Licensing Agreement, Maximum Milestone Payment Opening balance before adjustment, cumulative effect at date of initial application Opening balance before adjustment, cumulative effect at date of initial application [member] Total comprehensive income (loss) Comprehensive income Diluted income (loss) per share from continuing operations (in EUR per share) Diluted earnings (loss) per share from continuing operations Scientific advisory and consulting Scientific Advisory And Consulting The amount of Scientific advisory and consulting. Disclosure of net defined benefit liability (asset) Disclosure of net defined benefit liability (asset) [text block] IPH5201 agreement, with AstraZeneca, initial payment Agreement Related To IPH5201 With AstraZeneca, Initial Payment [Member] Agreement Related To IPH5201 With AstraZeneca, Initial Payment Document Fiscal Period Focus Document Fiscal Period Focus Transfer from collaboration liabilities Transfer from collaboration liabilities Transfer From (To) Collaboration Liabilities The decrease in contract liabilities resulting from transfer to collaboration liabilities. IPH6101 agreement, with Sanofi of which Sanofi agreement 2016 Agreement Related To IPH6101 With Sanofi [Member] Agreement Related To IPH6101 With Sanofi TOTAL ASSETS Assets Revenue from collaboration agreements Tax Effect Of Revenue From Collaborations With Customers The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenue from collaborations with customers. 2016 free preferred shares 2016 Free Preferred Shares [Member] Related to the 2016 free preferred shares. Income tax Description of accounting policy for income tax [text block] Borrowing, grace period Borrowing, Grace Period Borrowing, Grace Period AGA New Members 2024-1 AGA New Members 2024 - 1 Management AGA New Members 2024-1 Management [Member] AGA New Members 2024-1 Management Number of other equity instruments outstanding in share-based payment arrangement (in shares) Balance at beginning of period Balance at end of period Number of other equity instruments outstanding in share-based payment arrangement (in shares) Number of other equity instruments outstanding in share-based payment arrangement Definitive acquisition of free shares Definitive Acquisition Of Free Shares [Member] Definitive Acquisition Of Free Shares Income tax benefit / (expense) Current tax expense (income) and adjustments for current tax of prior periods Trading Symbol Trading Symbol Receivables Amounts receivable, related party transactions Types of interest rates [axis] Types of interest rates [axis] Security interest on pledge of financial instruments released Security Interest On Pledge Of Financial Instruments Released Security Interest On Pledge Of Financial Instruments Released Total revenue and other income Revenue Total, acquisitions Total, Acquisitions The increase in short-term investments and non-current financial assets resulting from origination or purchase. Entity Address, City or Town Entity Address, City or Town AGA Perf Management 2024-2 AGA Perf Management 2024-2 [Member] AGA Perf Management 2024-2 AGA Perf Management 2018 AGA Perf Management 2018 [Member] This member stands for AGA Perf Management 2018. Share capital Issued capital [member] Cumulative effect at date of initial application [axis] Cumulative effect at date of initial application [axis] Loan – Building Loan, building Loan, Building [Member] This member stands for loan, building. Classes of other provisions [domain] Classes of other provisions [domain] Other reserves Other reserves [member] Sanofi options Sanofi Options [Member] Sanofi Options Tax credit retentions 2025, CIR Tax Credit Retentions 2025, CIR Tax Credit Retentions 2025, CIR State guaranteed loans - accrued interest PGE Loan Agreement, Accrued Interest [Member] PGE Loan Agreement, Accrued Interest Expected decrease in number of employees, percentage Expected Decrease In Number Of Employees, Percentage Expected Decrease In Number Of Employees, Percentage Entity Emerging Growth Company Entity Emerging Growth Company Proceeds from collaboration and licensing agreements Collaboration And Licensing Agreements [Member] This member stands for collaboration and licensing agreements. Exercise and subscription of equity instruments through conversion Increase (Decrease) Through Conversion Of Equity Instruments Equity The amount of increase (decrease) through conversion of equity instruments. Increase capital, net (in shares) Increase (decrease) in number of ordinary shares issued Acquisition of other assets Purchase of other long-term assets, classified as investing activities AGA Perf Employees 2023-1 AGA Perf Employees 2023-1 [Member] AGA Perf Employees 2023-1 Maximum amount receivable from counter party upon achievement of certain development milestones Maximum Amount Receivable From Counter Party Upon Achievement Of Certain Development Milestones The maximum amount receivable from counter party upon achievement of certain development milestones. Lease liabilities - Printers Lease Financing Obligations, Printers [Member] Lease Financing Obligations, Printers Other non-current assets Other non-current non-financial assets Income tax benefit / (expense) calculated at statutory tax rate Tax expense (income) at applicable tax rate AGA Perf Management 2022-1 AGA Perf Management 2022-1 [Member] AGA Perf Management 2022-1 Prepaid expenses Current prepaid expenses Current prepaid expenses In progress Construction in progress [member] AGA Perf Management 2019-1 AGA Perf Management 2019-1 [Member] AGA Perf Management 2019-1 ASSETS Assets [abstract] Sanofi options IPH5201 [Member] This member stands for IPH5201. Right-of-use assets Right-of-use assets [member] Percentage of profits in Europe Percentage Of Profits In Europe The percentage of profits in Europe. Retained earnings Retained earnings, excluding profit (loss) for reporting period Current assets Current assets [abstract] Type of Exercise And Subscription Of Shares [Axis] Type of Exercise And Subscription Of Shares [Axis] Type of Exercise And Subscription Of Shares Disclosure of changes in deferred revenue and collaboration liabilities Explanation of significant changes in contract assets and contract liabilities [text block] Trade payables and others Trade Payables And Others [Member] This member stands for trade payables and others. Other payables Other current payables Entity Address, Postal Zip Code Entity Address, Postal Zip Code Non-current assets Non-current assets [abstract] Non-audit fees (services other than the audit of financial statements) Auditor's remuneration for other services Acquisitions Additions other than through business combinations, property, plant and equipment including right-of-use assets General and administrative expenses General and administrative expense Income Tax Disclosure of income tax [text block] AGA Perf Management 2019 AGA Perf Management 2019 [Member] Related to the plan. Revenue Description of accounting policy for recognition of revenue [text block] Fx impact Foreign Exchange Gain (Loss), Non Current Contract Liabilities Foreign Exchange Gain (Loss), Non Current Contract Liabilities Financial liabilities down payment at beginning of period Financial liabilities down payment at end of period Financial Liabilities Down Payment The amount of down payment in connection with the financial liabilities. Disclosure of tax rate reconciliation Disclosure Of Tax Rate Reconciliation [Text Block] The disclosure of tax rate reconciliation. State guaranteed loan BNP Paribas PGE loan agreement, BNP Paribas PGE Loan Agreement, BNP Paribas [Member] PGE Loan Agreement, BNP Paribas Short-term investments, variation of accrued interest Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss Related party transactions [abstract] Related party transactions [abstract] Personnel expenses other than share-based compensation Personnel expenses other than share-based compensation Short-term employee benefits expense Number of additional targets Number Of Additional Targets Number Of Additional Targets Shares issued for the acquisition of C5aR intangible asset (in shares) Shares Issued For The Acquisition Of C5aR Intangible Asset (In Shares) The increase (decrease) in the number of shares issued resulting from the acquisition of licenses. Total, variance of accrued interest Increase (Decrease) In Accrued Interest For Short-term And Non-current Financial Assets Not At Fair Value Through Profit Or Loss The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss. Adjustment for share instruments (in shares) Dilutive effect of convertible instruments on weighted average number of ordinary shares Types of financial assets Types of financial assets [domain] Trade receivables and others Trade Receivables And Others [Member] This member stands for trade receivables and others. Number of internal conditions performance, free performance shares Number Of Internal Conditions Performance, Free Performance Shares Number Of Internal Conditions Performance, Free Performance Shares Cash and cash equivalents Cash And Cash Equivalent [Member] This member stands for cash and cash equivalents. Share-based payment Increase (decrease) through share-based payment transactions, equity Leasing and maintenance Leasing And Maintenance The amount of leasing and maintenance. Basic income (loss) per share from discontinued operations (in EUR per share) Basic earnings (loss) per share from discontinued operations Foreign currency translation gain (loss) Foreign currency translation (loss) gain Other comprehensive income, net of tax, exchange differences on translation of foreign operations Total non-current assets Non-current assets AGA Employees 2016-1  AGA Employees 2016-1 [Member] This member stands for AGA Employees 2016-1. Share issue related cost Share issue related cost Disclosure of defined benefit plans [table] Disclosure of defined benefit plans [table] Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Impairment of intangibles assets, property, and equipment Description of accounting policy for impairment of assets [text block] Classes of property, plant and equipment [domain] Classes of property, plant and equipment [domain] Entity Address, Country Entity Address, Country Other financial expenses Other Financial Expenses The amount of other financial expenses. Reconciliation of changes in intangible assets other than goodwill [abstract] Reconciliation of changes in intangible assets other than goodwill [abstract] BSAAR 2012 BSAAR 2012 [Member] This member stands for BSAAR 2012. Sponsor of trial Number Of Partners Sponsoring Trial Costs Number Of Partners Sponsoring Trial Costs Risk-free interest rate Risk Free Interest Rate Other Equity Instruments Granted The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for other equity instruments granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). Other long term benefits, years of service, threshold three Other Long Term Benefits, Years Of Service, Threshold Three Other Long Term Benefits, Years Of Service, Threshold Three Effect of the exchange rate changes Effect of exchange rate changes on cash and cash equivalents Interest received on financial assets Interest received, classified as investing activities Research tax credit Research Tax Credit The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to research tax credit. Disclosure of audit and non-audit fees Disclosure Of Audit And Non-audit Fees [Table Text Block] The disclosure for audit and non-audit fees. Translation of transactions denominated in foreign currency Description of accounting policy for foreign currency translation [text block] Document Annual Report Document Annual Report Income Tax [Abstract] Income Tax [Abstract] Non-current contract liabilities at beginning of period Non-current contract liabilities at end of period Non-current contract liabilities IPH5201 agreement, with AstraZeneca, milestone payment Agreement Related To IPH5201 With AstraZeneca, Milestone Payment [Member] Agreement Related To IPH5201 With AstraZeneca, Milestone Payment Research tax credit Research Tax Credit, Receivable, Current The amount of current research tax credits. Disclosure of detailed information about financial instruments [table] Disclosure of detailed information about financial instruments [table] Geographical areas [domain] Geographical areas [domain] Revenue and government financing for research expenditures Disclosure of revenue [text block] Trade receivables and others - current Receivables and others - current Trade and other current receivables Receipts from co-development agreement and option agreement Receipts From Codevelopment Agreement And Option Agreement The cash inflow from co-development agreement and option agreement. The company Disclosure Of Company, Significant Contracts And Key Events [Text Block] The disclosure of the company, significant agreements description and key events. Entity Interactive Data Current Entity Interactive Data Current R&D Research And Development [Member] Research And Development AGA New Members 2017-1 AGA New Members 2017-1 [Member] This member stands for AGA New Members 2017-1. Disclosure of government financing for research expenditures Disclosure Of Government Financing For Research Expenditures [Table Text Block] The disclosure of government financing for research expenditures. Loans – Equipment Loan, Equipment [Member] This member stands for loan, equipment. Sanofi-Aventis Sanofi-Aventis [Member] Sanofi-Aventis Financial expenses Financial expenses Finance costs Agreements with Sanofi for NK Cell engages Agreements with Sanofi for NK Cell engages [Member] Agreements with Sanofi for NK Cell engages Cash, cash equivalents and financial assets Disclosure of financial assets [text block] BSAAR BSAAR [Member] This member stands for BSAAR. Accounting policies and statement of compliance Disclosure of material accounting policy information [text block] Number of instruments with potential future dilutive effect not included in calculation of diluted earnings per share (in shares) Number Of Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share The number of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future, but were not included in the calculation of diluted earnings per share because they are antidilutive for the period(s) presented. BSA 2013 BSA 2013 [Member] This member stands for BSA 2013. Auditor [Table] Auditor [Table] Entity Central Index Key Entity Central Index Key AGA "Plan Epargne Entreprise" 2022 AGA "Plan Epargne Entreprise" 2022 [Member] AGA "Plan Epargne Entreprise" 2022 2017 free preferred shares 2017 Free Preferred Shares [Member] Related to the 2017 free preferred shares. Net collection (payments) Cash repayments of advances and loans from related parties Deferred tax assets / Tax amortization Tax Amortization [Member] Tax Amortization Expected dividends Expected dividends Expected Dividend Other Equity Instruments Granted The amount of an expected dividend used to calculate the fair value of other equity instruments granted. LIABILITIES AND SHAREHOLDERS' EQUITY Equity and liabilities [abstract] Medimmune Limited Medimmune Limited [Member] Medimmune Limited Reconciliation of changes in property, plant and equipment [abstract] Reconciliation of changes in property, plant and equipment [abstract] Entity Filer Category Entity Filer Category Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement Monalizumab Rights Under The 2014 Monalizumab (NKG2A) Novo Nordisk Agreement [Member] This member stands for Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement. Subsciption of share warrants Subscription Of Share Warrants [Member] Subscription Of Share Warrants Average rate (€1 equals to USD) Average foreign exchange rate Company Information [Line Items] Company Information [Line Items] Company Information [Line Items] Non-current financial assets, variation of accrued interest Increase (Decrease) In Accrued Interest For Non-current Financial Assets Not At Fair Value Through Profit Or Loss The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss. Operating income (loss) Profit (loss) from operating activities Short-term investments Short-term Investment [Member] This member stands for short-term investments. Other receivables Other current receivables Clinical Services Clinical Services [Member] Clinical Services Audit fees Auditor's remuneration for audit services Restructuring impact Increase (decrease) in net defined benefit liability (asset) resulting from miscellaneous other changes Entity Address, Address Line One Entity Address, Address Line One Non-recognition of deferred tax assets related to tax losses and temporary differences Tax Effect Of Non-recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to non-recognition of deferred tax assets related to tax losses and temporary differences. Employee benefits costs Adjustments for increase (decrease) in employee benefit liabilities Disclosure of breakdown of expenses per financial year Explanation of effect of share-based payments on entity's profit or loss [text block] Other profit or loss items with no cash effect Other adjustments to reconcile profit (loss) Extra pension benefits Key Management Personnel Compensation Extra Pension Benefits Key Management Personnel Compensation Extra Pension Benefits Loan agreement, collateral Loan Agreement Collateral The value of collateral in connection with the loan agreement. 2015 monalizumab agreement, with AstraZeneca 2015 AstraZeneca Monalizumab Agreements [Member] This member stands for 2015 AstraZeneca monalizumab agreements. Other financial income Other Financial Income The amount of other financial income. Others Other Product And Services [Member] Other Product And Services Statement of cash flows [abstract] Statement of cash flows [abstract] Prepaid expenses Non-Current Prepaid Expenses Non-Current Prepaid Expenses Disclosure of financial assets [Table] Disclosure of financial assets [table] Number of other equity instruments exercisable in share-based payment arrangement (in shares) Number of other equity instruments exercisable in share-based payment arrangement (in shares) Number of other equity instruments exercisable in share-based payment arrangement Counterparty Name [Domain] Counterparty Name [Domain] Current Current contract liabilities [abstract] Fair value per AGA (in EUR per share) Fair value per BSA (in EUR per share) Fair Value Per Share At Grant Date Other Equity Instruments Granted The fair value per share at grant date of other equity instruments granted. Current liabilities Current liabilities [abstract] Financial liabilities—current portion Financial Liabilities, Current Portion [Member] This member stands for financial liabilities—current portion. Characteristics of defined benefit plans Characteristics of defined benefit plans [domain] Auditor Remuneration [Table] Auditor Remuneration [Table] Auditor Remuneration AGA Perf Employees 2020-1 AGA Perf Employees 2020-1 [Member] AGA Perf Employees 2020-1 Monalizumab Agreement of which monalizumab agreement - AstraZeneca Monalizumab Agreement [Member] This member stands for monalizumab agreement. Disclosure of transactions between related parties [Line Items] Disclosure of transactions between related parties [line items] Number of therapeutic approaches Number Of Therapeutic Approaches Number Of Therapeutic Approaches 2014 Novo Nordisk A/S monalizumab agreement 2014 Novo Nordisk A/S Monalizumab Agreement [Member] This member stands for 2014 Novo Nordisk A/S monalizumab agreement. BSA-2025-1 BSA-2025-1 [Member] BSA-2025-1 Classes of share capital Classes of share capital [domain] Percentage of revenue denominated in US dollars Percentage Of Revenue Denominated In US Dollars The percentage of revenue that denominated in US dollars. Disclosure of terms and conditions of other equity instruments Disclosure of terms and conditions of share-based payment arrangement [text block] Actuarial assumption of expected rates of salary increases Annual rate of increase in wages Actuarial assumption of expected rates of salary increases Monalizumab Monalizumab [Member] This member stands for Monalizumab. Financial income Financial income Finance income Classes of financial liabilities [axis] Classes of financial liabilities [axis] Classes of financial liabilities Classes of financial liabilities [domain] Document Shell Company Report Document Shell Company Report Milestone payments, percentage Milestone Payments, Percentage Milestone Payments, Percentage Disposal of non-current financial instruments Disposal Of Non-current Financial Instruments The cash inflow from the disposal of non-current financial instruments. Proportion of nominal value deconsolidated receivables, CIR 2023 Percentage of Pre-Financed CIR Collected Percentage of Pre-Financed CIR Collected AGAP Perf Management 2018-1 AGAP Perf Management 2018-1 [Member] This member stands for AGA Perf Management 2018-1. Additions Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities Average number of employees Average number of employees Proceeds Increase Through Upfront Payment Contract Liabilities The increase in contract liabilities resulting from upfront payment. Lease liabilities – Real estate property Lease Financing Obligations, Real Estate Property [Member] This member stands for lease finance obligations, real estate property. AGA employees 2025-01 AGA Employees 2025-01 [Member] AGA Employees 2025-01 Cash And Cash Equivalents And Financial Assets [Abstract] Cash And Cash Equivalents And Financial Assets Provisions – non-current portion Non-current provisions Actuarial assumption of discount rates Discount rate (iBoxx Corporate AA) for retirement Actuarial assumption of discount rates Exercise and subscription of equity instruments Exercise and subscription of equity instruments Exercise And Subscription Of Equity Instruments The increase (decrease) in equity resulting from exercise and subscription of equity instruments. Change in working capital Change In Working Capital The amount of working capital. AGA Perf Management 2020-1 AGA Perf Management 2020-1 [Member] AGA Perf Management 2020-1 Non cash effects : proceeds from lease liabilities and other Proceeds From Lease Liabilities And Other Non Cash Effects, Classified As Financing Activities The amount of proceeds from lease liabilities. Other revenue, reinvoicing external expenses under agreement Other Revenue, Reinvoicing External Expenses Under Agreement Other Revenue, Reinvoicing External Expenses Under Agreement Net income (loss) from continuing operations Profit (loss) from continuing operations Transfers Increase (decrease) through transfers, intangible assets other than goodwill Disclosure of number and weighted average exercise prices of other equity instruments Disclosure of number and weighted average exercise prices of other equity instruments [text block] Share capital Issued capital Other intangible assets Other intangible assets [member] Trade and other non-current receivables [abstract] 35-39 years Actuarial Assumption Of Annual Turnover Rate By Age 35-39 Years The annual turnover rate for 35-39 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation. Categories of financial assets [axis] Categories of financial assets [axis] Subcontracting costs Subcontracting Costs The amount of subcontracting costs. Other long term benefits, years of service, threshold one Other Long Term Benefits, Years Of Service, Threshold One Other Long Term Benefits, Years Of Service, Threshold One Number of shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Number of shares outstanding Executives Executives [Member] This member stands for executives. Products and services [axis] Products and services [axis] Other temporary differences Other temporary differences [member] Total financial liabilities Financial liabilities Financial liabilities at beginning of period Financial liabilities at end of period Financial liabilities Operating expenses Operating Expense [Abstract] Operating Expense Income tax expense Income tax benefit / (expense) Tax expense (income) BSA 2011-2 BSA 2011-2 [Member] Related to the plan. Events after the reporting date Disclosure of events after reporting period [text block] Stock Options 2020-1 Stock Options 2020-1 [Member] Stock Options 2020-1 Disclosure of information about defined benefit plans [abstract] Disclosure of information about defined benefit plans [abstract] Number of employees Number of employees AGAP Employee 2024/ AGAP Management 2024 AGAP Employee 2024/ AGAP Management 2024 [Member] AGAP Employee 2024/ AGAP Management 2024 Document Transition Report Document Transition Report Disclosure of cash, cash equivalents and financial assets Disclosure Of Cash, Cash Equivalents And Financial Assets [Text Block] The disclosure of cash, cash equivalents and financial assets. Trade receivables and others (excluding rebates related to capital expenditures) Trade receivables and others Trade and other receivables Guarantees Guarantees [member] Company Information [Table] Company Information [Table] Company Information [Table] Interests and gains on financial assets Interests And Gains On Financial Assets The amount of interests and gains on financial assets. Disclosure of defined benefit plans [line items] Disclosure of defined benefit plans [line items] Document Period End Date Document Period End Date Disclosure of changes in the share capital Disclosure of classes of share capital [line items] Maturity [axis] Maturity [axis] Advance received - exclusive license Revenue From Contracts With Customers, Advance Payment Received, Licenses Revenue From Contracts With Customers, Advance Payment Received, Licenses Beginning balance, total Ending balance, total Short-term Investments And Non-current Financial Assets The amount of short-term investments and non-current financial assets. Deferred tax liabilities / Lease contract (IFRS 16 application) Lease Contract [Member] Lease Contract Auditor Information [Abstract] Auditor Information [Abstract] Auditor Information Document Type Document Type Expense from share-based payment transactions with employees Share-based compensation Share-based compensation Expense from share-based payment transactions with employees Cash, cash equivalents, and financial assets denominated in US dollars Cash, Cash Equivalents, And Financial Assets Denominated In US Dollars [Member] Related to cash, cash equivalents, and financial assets denominated in US dollars. Classes of financial assets [axis] Classes of financial assets [axis] Total, foreign currency effect Total, Foreign Currency Effect The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements. Annual mobility rate Actuarial Assumption of Annual Mobility Rate The amount of annual mobility rate of actuarial assumptions. Current contract liabilities at beginning of period Current contract liabilities at end of period Current contract liabilities Statistical Measurement [Axis] Statistical Measurement [Axis] Disclosure of financial liabilities [abstract] Maximum potential regulatory milestones Maximum Potential Regulatory Milestones Maximum Potential Regulatory Milestones Provisions – current portion Current provisions 2030 Later than four years and not later than five years [member] Types of share-based payment arrangements Types of share-based payment arrangements [domain] Deferred tax assets / Tax losses carryforwards - France FRANCE Range [axis] Range [axis] Components of equity [axis] Components of equity [axis] Fixed interest rate Fixed interest rate [member] Financial liabilities Disclosure of financial liabilities [text block] Disclosure of financial liabilities [Line Items] Disclosure of financial liabilities [line items] Net income (loss) before tax Profit (loss) before tax Advisory fees Key Management Personnel Compensation, Advisory Fees Key Management Personnel Compensation, Advisory Fees of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the progress of related research program Agreement Related To ANKET IPH67 With Sanofi [Member] Agreement Related To ANKET IPH67 With Sanofi BSA 2022-1 BSA 2022-1 [Member] BSA 2022-1 Entity's total for related parties Categories of related parties [domain] AGA Bonus 2022-1 [Member] AGA Bonus 2022-1 [Member] AGA Bonus 2022-1 Disclosure of disaggregation of revenue from contracts with customers [abstract] Disclosure of disaggregation of revenue from contracts with customers [abstract] Significant Accounting Policies [Abstract] Significant Accounting Policies [Abstract] AGA Employee 2025 AGA Employee 2025 [Member] AGA Employee 2025 Average life of BSA Average Life Other Equity Instruments Granted The average life of other equity instruments granted. Potential additional milestone payments Potential Additional Milestone Payments Potential Additional Milestone Payments Foreign exchange variation Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement Share-based payment transactions with employees, awards, expected term (year) Share-based Payment Transactions With Employees Awards Expected Term The expected term of awards granted in a share-based payment transactions. Auditor Location Auditor Location Interest received Interest received, classified as operating activities Security interest on pledge of financial instruments will be released in 2031 Security Interest On Pledge Of Financial Instruments Will Be Released In 2031 The values of Security interest on pledge of financial instruments will be released in 2024. Foreign exchange losses Net foreign exchange loss Recently issued accounting standards and interpretations Description Of Accounting Policy For New IFRS Releases [Policy Text Block] The description of the entity's accounting policy for new IFRS releases. Products and services Products and services [domain] Weighted average number of ordinary shares in circulation (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share AGA Employee 2017 AGA Employees 2017 [Member] This member stands for AGA Employees 2017. AGA Perf Management 2023-1 AGA Perf Management 2023-1 [Member] AGA Perf Management 2023-1 Share-based compensation Tax Effect Of Share-based Compensation The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based compensation. Disclosure of temporary difference, unused tax losses and unused tax credits Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Prepayments made to suppliers Current advances to suppliers Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Other reserves Other reserves Share-based compensation Key management personnel compensation, share-based payment Share price (in EUR per share) Issue of Equity, Share Price Issue of Equity, Share Price Total borrowings Borrowings Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Executives, born after 1968 Executives, Born After 1968 [Member] Executives, Born After 1968 Commercialization milestones Commercialization Milestones The commercialization milestones pursuant to the agreement. Security interest on pledge of financial instruments will be released in 2024 Security Interest On Pledge Of Financial Instruments Will Be Released In 2024 The values of security interest on the pledge of financial instruments will be released in 2024. Computers and IT equipment Computer equipment [member] Net increase / (decrease) in cash and cash equivalents Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Co-fund percentage of trials of licensed product Co-fund Percentage Of Trials Of Licensed Product The co-fund percentage of trials of licensed product. Security interest on pledge of financial instruments will be released in 2027 Security Interest On Pledge Of Financial Instruments Will Be Released In 2027 The values of security interest on pledge of financial instruments will be released in 2027. AGA Employees 2018 AGA Employees 2018 [Member] Related to the plan. Borrowings, maturity period Borrowings, Maturity Period Borrowings, Maturity Period Net cash generated from / (used in) financing activities Cash flows from (used in) financing activities Counterparties [axis] Counterparties [axis] Earnings (loss) per share Description of accounting policy for earnings per share [text block] Preferred shares Preference shares [member] Termination notice period (in days) Termination Notice Period Termination Notice Period Management of financial risks and fair value Disclosure of nature and extent of risks arising from financial instruments [text block] Entity Current Reporting Status Entity Current Reporting Status Length of service awards Length Of Service Awards [Member] Length Of Service Awards Statement of changes in equity [table] Statement of changes in equity [table] Repayments of borrowings, down payment Decrease In Down Payment The decrease in down payment. Current Fiscal Year End Date Current Fiscal Year End Date Disposal of property and equipment Proceeds from sales of property, plant and equipment, classified as investing activities 40-44 years Actuarial Assumption Of Annual Turnover Rate By Age 40-44 Years The annual turnover rate for 40-44 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation. Bottom of range Bottom of range [member] AGAP Employee 2023/ AGAP Management 2023 AGAP Employee 2023 / AGAP Management 2023 [Member] AGAP Employee 2023-1 / AGAP Management 2023 Public Other Individual Shareholders [Member] Other Individual Shareholders Categories of related parties [axis] Categories of related parties [axis] Debt at amortized cost Financial liabilities at amortised cost, category [member] Implementation of environmental or social actions by employees Number of Environmental or Social Actions Implemented Number of Environmental or Social Actions Implemented Impairment Impairment Loss [Member] Impairment Loss Milestone payment received - option exercised Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised Net income (loss) Net income (loss) for the period Net income (loss) Net loss Net loss for the period Profit (loss) Issue shares for licenses Issue Shares For Licenses The value of shares issued related to licenses. Non-current financial assets, foreign currency effect Non-current Financial Assets, Foreign Currency Effect The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements. Financial assets Financial assets of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program Agreement Related To ANKET IPH62 With Sanofi [Member] Agreement Related To ANKET IPH62 With Sanofi Financial liabilities—non-current portion Financial Liabilities, Non-current Portion [Member] This member stands for financial liabilities—non-current portion. Total non-current liabilities Non-current liabilities Unused tax losses with no expiration date Unused Tax Losses With No Expiration Date The amount of unused tax losses with no expiration date. Closing rate (€1 equals to USD) Closing foreign exchange rate Short-term investments, disposals Decrease Through Derecognition Short-term Investment The decrease in current investment resulting from derecognition. Document Registration Statement Document Registration Statement Balance at beginning of period (in shares) Balance at end of period (in shares) Total number of shares issued (in shares) Number of shares issued AGA Employees 2025-1 AGA Employees 2025-1 [Member] AGA Employees 2025-1 Temporary difference, unused tax losses and unused tax credits Temporary difference, unused tax losses and unused tax credits [domain] AGA Bonus 2018-1 AGA Bonus 2018-1 [Member] Related to the plan. Net financial income (loss) Disclosure of finance income (cost) [text block] 2027 Later than one year and not later than two years [member] Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Leases Description of accounting policy for leases [text block] Financial liabilities, fair value Financial Liabilities Trade Payables And Others At Fair Value The fair value of financial liabilities, trade payables and other. Disclosure of net financial loss Disclosure Of Net Financial Income (Loss) [Table Text Block] The disclosure of net financial income (loss). Share Capital And Share Based Payments [Abstract] Share Capital And Share Based Payments [Abstract] Analysis of income and expense [abstract] Analysis of income and expense [abstract] Upfront payment, shares issued Upfront Payment Shares Issued The value of shares issued for the upfront payments. Company Information [Abstract] Company Information [Abstract] Company Information Depreciation and amortization Depreciation and amortisation expense Business Contact Business Contact [Member] Payments (benefits and contributions paid by the employer) Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan Categories of financial assets Categories of financial assets [domain] Period of Birth [Axis] Period of Birth [Axis] Period of Birth Transfers Increase (decrease) through transfers from construction in progress, property, plant and equipment including right-of-use assets Income from research tax credit 2019 Income From Research Tax Credit 2019 Income From Research Tax Credit 2019 AGA Bonus 2018 AGA Bonus 2018 [Member] This member stands for AGA Bonus 2018. AGAP Employees 2016-1 AGAP Employees 2016-1 [Member] This member stands for AGAP Employees 2016-1. Consolidation method Description Of Accounting Policy For Consolidation Method [Policy Text Block] The description of the entity's accounting policy for consolidation method. Personnel expenses and other short-term employee benefits Key management personnel compensation, short-term employee benefits Security Exchange Name Security Exchange Name Income from research tax credit 2023 Income From Research Tax Credit 2023 Income From Research Tax Credit 2023 Net defined benefit liability (asset) at beginning of period Net defined benefit liability (asset) at end of period Net defined benefit liability (asset) Income from research tax credit 2020 Income From Research Tax Credit 2020 Income From Research Tax Credit 2020 Preclinical Services Preclinical Services [Member] Preclinical Services Defined benefit obligations Non-current provisions for employee benefits AGA Perf Employees 2020-1 / AGA Perf Management 2020 AGA Perf Employees 2020-1 / AGA Perf Management 2020 [Member] AGA Perf Employees 2020-1 / AGA Perf Management 2020 Contact Personnel Name Contact Personnel Name Withholding rate realized by CIR Withholding Rate , CIR Withholding Rate , CIR Tax and employee-related payables Payables on social security and taxes other than income tax PricewaterhouseCoopers PricewaterhouseCoopers [Member] PricewaterhouseCoopers Proceeds from exercise of option agreement Proceeds From Exercise Of Option Agreement The cash inflow from the exercise of option agreement. Beginning balance, current investments Ending balance, current investments Current investments AGA Bonus 2017 AGA Bonus 2017 [Member] This member stands for AGA Bonus 2017. AGAP Management 2017-1 AGAP Management 2017-1 [Member] Related to a plan. Number of loans Number Of Loans Number Of Loans Differences in tax rates Differences In Tax Rates The amount of tax effect from differences in tax rates. Vesting period (years) Vesting period (years) Vesting Period Other Equity Instruments Granted The vesting period of other equity instruments granted. Elements which will be reclassified in the consolidated statement of income (loss): Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Contract liabilities at beginning of period Contract liabilities at end of period Contract liabilities Financial assets, fair value Financial assets, at fair value Net receivables (liabilities) Net Amounts Receivable (Payable) Related Party Transactions The net amounts of receivables (payable) resulting from related party transactions. Borrowing, number of loan agreement Borrowing, Number Of Loan Agreement Borrowing, Number Of Loan Agreement Statistical Measurement [Domain] Statistical Measurement [Domain] Impairment Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill AGA Perf Employees 2019-1 AGA Perf Employees 2019-1 [Member] AGA Perf Employees 2019-1 Advance received - research work Revenue From Contracts With Customers, Advance Payment Received, Research Revenue From Contracts With Customers, Advance Payment Received, Research Deferred tax assets / Tax losses carryforwards Unused tax losses [member] Change in accounting policies Description Of Accounting Policy For Change In Accounting Policies [Policy Text Block] The description of accounting policy for change in accounting policies. Total operating expenses Operating expense Amortisation period, intangible assets other than goodwill Useful life measured as period of time, intangible assets other than goodwill Upfront payment, cash Upfront Payment Cash The amount of cash paid for the the upfront payments. Intellectual property expenses Intellectual Property Expenses The amount of intellectual property expenses. Classes of share capital [axis] Classes of share capital [axis] AGAP Employee 2022 / AGAP Management 2022 AGAP Employee 2022 / AGAP Management 2022 [Member] AGAP Employee 2022 / AGAP Management 2022 Fx impact Foreign Exchange Gain (Loss), Current Contract Liabilities Foreign Exchange Gain (Loss), Current Contract Liabilities Impact linked to the exercise of a real estate leasing option Tax Effect Of Exercise Of Real Estate Leasing Option Tax Effect Of Exercise Of Real Estate Leasing Option Total shareholders’ equity Balance at beginning of period Balance at end of period Total equity Equity Loan agreement, maximum borrowing capacity Loan Agreement Maximum Borrowing Capacity Maximum borrowing capacity under the loan agreement. Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Short-term investments, acquisitions Short-term Investments, Acquisitions The increase in current investment resulting from origination or purchase. Lease liabilities – Premises Innate Inc. Lease Financing Obligations, Innate Inc. Premises [Member] Related to the lease financing obligations for the Innate Inc. premises. Exercise and subscription of equity instruments through conversion (in shares) Increase (Decrease) In Number Of Shares Issued From Conversion Of Equity Instruments The number of increase (decrease) in shares issued from the conversion of equity instruments. Sanofi-Aventis Participations Sanofi-Aventis Participations [Member] Sanofi-Aventis Participations Types of contracts Types of contracts [domain] Corporate information and statement of IFRS compliance [abstract] Items which will not be reclassified in the consolidated statement of income (loss): Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Income (Loss) Per Share [Abstract] Income (Loss) Per Share [Abstract] AGAP Employees 2017-1 AGAP Employees 2017-1 [Member] Related to a plan. Disclosure of detailed information about property, plant and equipment [Line Items] Disclosure of detailed information about property, plant and equipment [line items] AGA Perf Employees 2022-1 AGA Perf Employees 2022-1 [Member] AGA Perf Employees 2022-1 Disclosure of non-adjusting events after reporting period [abstract] Disclosure of non-adjusting events after reporting period [abstract] PwC Price Waterhouse Cooper (PWC) [Member] Price Waterhouse Cooper (PWC) Marketing, communication and public relations Sales and marketing expense Deferred tax liabilities / Deferred revenue Contract Liabilities [Member] Contract Liabilities Change in provisions Adjustments for provisions Total current liabilities Current liabilities Maximum payments to counter party upon achievement of certain milestones Maximum Payments To Counter Party Upon Achievement Of Certain Milestones The maximum payments to counter party upon the achievement of certain commercial and regulatory milestones. G&A General And Administrative [Member] General And Administrative AGA "Plan Epargne Entreprise" 2024 AGA "Plan Epargne Entreprise" 2024 AGA "Plan Epargne Entreprise" 2024 [Member] AGA "Plan Epargne Entreprise" 2024 Deferred tax assets Deferred tax assets Lease liabilities – Building "Le Virage" Lease finance obligations – Rent Le Virage Lease Financing Obligations, Building, "Le Virage" [Member] Related to the finance lease obligations for the "Le Virage" building. Document Accounting Standard Document Accounting Standard Auditor [Line Items] Auditor [Line Items] Disclosure of trade payables and others Disclosure Of Trade Payables And Others [Text Block] The disclosure of trade payables and others. Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Additions Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities Share-based compensation Description of accounting policy for share-based payment transactions [text block] Statement of changes in equity [abstract] Statement of changes in equity [abstract] Exercise of option Revenue From Contracts With Customers, Exercise Of Option The amount of revenue from contracts with customer recognized by exercise of option. Maximum amount receivable from counter party upon achievement of certain milestones Maximum Amount Receivable From Counter Party Upon Achievement Of Certain Milestones The maximum amount that receivable from counter party upon achievement of certain development and regulatory milestones and commercialization milestones. Provisions for employee benefits Provisions for employee benefits Disclosure of detailed information about financial instruments [line items] Disclosure of detailed information about financial instruments [line items] Repayment cost to AZ Decrease Through Repayments, Current Contract Liabilities Decrease Through Repayments, Current Contract Liabilities Buildings and improvements on buildings Buildings [member] Lease liabilities – Vehicles Lease Financing Obligations, Vehicles [Member] Related to the lease financing obligation for vehicles. 2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S 2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S [Member] 2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S Number of free shares granted (in shares) Granted during the period Number of other equity instruments granted in share-based payment arrangement Exercise period, terms Exercise Period, Terms Exercise Period, Terms Revenue and other income Revenue And Other Income Percentage of shareholding in the company Percentage of Shareholding In The Company Percentage of Shareholding In The Company Non-current financial assets, variation of fair value through the consolidated statement of income (loss) Non-current Financial Assets, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss) The gains (losses) on non-current financial assets at fair value through profit or loss. Trade receivables and others (excluding rebates related to capital expenditures), variance Adjustments for decrease (increase) in trade and other receivables Tax credit retentions 2024, CIR Tax Credit Retentions 2024, CIR Tax Credit Retentions 2024, CIR Interest paid, classified as operating activities Interest paid, classified as operating activities Write-off of a right-of-use asset Write-Off of a Right-Of-Use Asset Write-Off of a Right-Of-Use Asset Option exercise fee payable by counter party Option Exercise Fee Payable By Counter Party The amount of option exercise fee payable by the counter party. Advance received - additional targets Revenue From Contracts With Customers, Advance Payment Received, Target Options Revenue From Contracts With Customers, Advance Payment Received, Target Options Write-off of a lease liability Write-Off of a Lease Liability Write-Off of a Lease Liability Disclosure of financial liabilities [Table] Disclosure of financial liabilities [table] Segment information Description of accounting policy for segment reporting [text block] Geographical areas [axis] Geographical areas [axis] Borrowing, percentage of state-guaranteed loan Borrowing, Percentage Of State-Guaranteed Loan Borrowing, Percentage Of State-Guaranteed Loan Gains (losses) on assets and other financial assets Adjustments for finance income Non-executives, born after 1968 Non-executives, Born After 1968 [Member] Non-executives, Born After 1968 Impact linked to intra-group merger operations Tax Effect Of Intra-Group Merger Operations Tax Effect Of Intra-Group Merger Operations Trade payables and others excluding payables related to capital expenditures Current Trade Payables And Others Excluding Payables Related To Capital Expenditures The amount of current Trade payables and others, excluding payables related to capital expenditures. Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Cash, cash equivalents and short-term investments Cash and cash equivalents and short-term investments Cash, Cash Equivalents And Short-Term Investments, Assets The amount of cash, cash equivalents and short-term investments. BSAAR 2015 BSAAR 2015 [Member] This member stands for BSAAR 2015. Intangible assets Intangible assets other than goodwill at beginning of period Intangible assets other than goodwill at end of period Intangible assets other than goodwill Intangible assets other than goodwill Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Proportion of voting rights held in the company Proportion Of Voting Rights Held In The Company Proportion Of Voting Rights Held In The Company of which preclinical molecules agreement - AstraZeneca Preclinical Molecules Agreement With AstraZeneca [Member] Preclinical Molecules Agreement With AstraZeneca Disclosure of initial application of standards or interpretations [Line Items] Disclosure of initial application of standards or interpretations [line items] Disposals Disposals, intangible assets other than goodwill Number of new members appointed to the board of directors Number Of New Members Appointed To The Board Of Directors Number Of New Members Appointed To The Board Of Directors Cash and cash equivalents Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year Cash and cash equivalents Cash and cash equivalents Number of licensing agreements Number of Licensing Agreements Number of Licensing Agreements Cumulative 5% retained - Tax credit refund Cumulative Tax Credit Retentions, CIR Cumulative 5% Retention, CIR Increase (decrease) in employee benefit obligation per 25 basis point changes in discount rate Increase (Decrease) In Employee Benefit Obligation Per 25 Basis Point Changes In Discount Rate The amount increase (decrease) in employee benefit obligation per 25 basis point changes in discount rate. Disclosure of transactions between related parties Disclosure of transactions between related parties [text block] TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Equity and liabilities Deferred tax assets / Tax losses carry forwards - US UNITED STATES Property, plant and equipment [abstract] Property, plant and equipment [abstract] Provisions Provisions Land and buildings Land and buildings [member] Repayment cost to AZ Decrease Through Repayments Contract Liabilities The decrease in contract liabilities resulting from deductions. Period of Birth [Domain] Period of Birth [Domain] Period of Birth [Domain] BSA 2014 BSA 2014 [Member] This member stands for BSA 2014. Cost of supplies and consumable materials Raw materials and consumables used Raw materials and consumables used IPH5201 (Anti-CD39) rights acquired from Orega Biotech IPH5201 (Anti-CD39) Rights Acquired From Orega Biotech [Member] This member stands for IPH5201 (Anti-CD39) rights acquired from Orega Biotech. Disclosure of maturity analysis for non-derivative financial liabilities Disclosure of maturity analysis for non-derivative financial liabilities [text block] Disclosure of trade receivables and other Disclosure Of Trade Receivables And Other [Table Text Block] The disclosure of trade receivables and other. Laboratory equipment and other Laboratory Equipment And Other [Member] This member stands for laboratory equipment and other. Short-term investments, foreign currency effect Short-term Investments, Foreign Currency Effect The increase (decrease) in current financial assets resulting from foreign exchange and other movements. City Area Code City Area Code Treasury shares Innate Pharma, Treasury Stock [Member] Innate Pharma, Treasury Stock Borrowing, maturity Borrowing, Maturity Borrowing, Maturity PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S PH5401 (Anti-C5aR) Rights Acquired From Novo Nordisk A/S [Member] This member stands for PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S. AGA Perf Management 2021-1 AGA Perf Management 2021-1 [Member] AGA Perf Management 2021-1 Depreciation period, property, plant and equipment Useful life measured as period of time, property, plant and equipment Deferred Revenue, Roll Forward [Abstract] Deferred Revenue, Roll Forward [Abstract] Deferred Revenue, Roll Forward Volatility Expected volatility Expected Volatility Other Equity Instruments Granted The expected volatility of the share price used to calculate the fair value of the other equity instruments granted. Categories of financial liabilities Categories of financial liabilities [domain] >2030 Later than five years [member] Non transferability period (in years) Nontransferability Period Other Equity Instruments Granted The non-transferability period of other equity instruments granted. Related party transactions Disclosure of related party [text block] Classes of financial assets Classes of financial assets [domain] Payables related to capital expenditures Current Payables Related To Capital Expenditures The amount of current payables related to capital expenditures. Agreement with Takeda on research of Antibody Drug Conjugates (ADC) Agreement With Takeda on Research of Antibody Drug Conjugates (ADC) [Member] Agreement With Takeda on Research of Antibody Drug Conjugates (ADC) Intangible assets Disclosure of intangible assets [text block] VAT refund Current value added tax receivables Deferred tax assets, offset amount Deferred Tax Assets, Offset Amount Deferred Tax Assets, Offset Amount Disposals Disposals, property, plant and equipment including right-of-use assets Acquisitions Acquisitions through business combinations, intangible assets other than goodwill Trade payables and others (excluding payables related to capital expenditures) Trade and other payables Disclosure of classes of share capital [Table] Disclosure of classes of share capital [table] Auditor Name Auditor Name Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Grant date share fair value (in EUR per share) Grant date share fair value (in EUR per share) Grant Date Share Fair Value Other Equity Instruments Granted The grant date share fair value of other equity instruments granted. State guaranteed loan Société Générale PGE loan agreement, Societe Generale PGE Loan Agreement, Societe Generale [Member] PGE Loan Agreement, Societe Generale Trade receivables and others Disclosure of trade and other receivables [text block] Type of Exercise And Subscription Of Shares [Domain] Type of Exercise And Subscription Of Shares [Domain] Type of Exercise And Subscription Of Shares [Domain] Net cash generated from/ (used in) operating activities Cash flows from (used in) operating activities Number of other equity instruments forfeited in share-based payment arrangement (in shares) Forfeited during the period Number of other equity instruments forfeited in share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [Line Items] Disclosure of terms and conditions of share-based payment arrangement [line items] Number of directors Number Of Directors Number Of Directors AGA Bonus 2020-1 & 2 AGA Bonus 2020-1 & 2 [Member] AGA Bonus 2020-1 & 2 Non-current liabilities Non-current liabilities [abstract] Deferred revenue - current and non-current portion Deferred income including contract liabilities Total, variation of fair value through the consolidated statement of income (loss) Total, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss) The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss. Document Fiscal Year Focus Document Fiscal Year Focus Reconciliation of the net income (loss) and the cash generated from (used for) the operating activities Adjustments to reconcile profit (loss) [abstract] AGA Employees 2016-2 AGA Employees 2016-2 [Member] This member stands for AGA Employees 2016-2. Borrowing, maturity, extension period option Borrowing, Maturity, Extension Period Option Borrowing, Maturity, Extension Period Option AGAP Management 2017 AGAP Management 2017 [Member] This member stands for AGAP Management 2017. Number of own shares (in shares) Number of shares in entity held by entity or by its subsidiaries or associates Actuarial assumption of retirement age Age at retirement Actuarial assumption of retirement age Loan agreement with Société Générale Loan Agreement With Société Générale [Member] This member stands for loan agreement with Société Générale. Financial liabilities – current portion Current financial liabilities Disclosure of detailed information about financial instruments Disclosure of detailed information about financial instruments [text block] Milestone payments, maximum amount Milestone Payments, Maximum Amount Milestone Payments, Maximum Amount Basis of preparation Description Of Accounting Policy For Basis Of Preparation [Policy Text Block] The description of the entity's accounting policy for basis of preparation. Types of interest rates Types of interest rates [domain] Other income Other income Classes of other provisions [axis] Classes of other provisions [axis] American Depository Shares American Depository Shares [Member] American Depository Shares Disclosure of change in number of other equity instruments outstanding Disclosure Of Change In Number Of Other Equity Instruments Outstanding [Table Text Block] Disclosure of change in number of other equity instruments outstanding. Collaboration liabilities - current and non-current portion Collaboration Liabilities The amount of collaboration liabilities. Disclosure of depreciation periods Disclosure Of Depreciation Periods [Table Text Block] The disclosure of depreciation period. Additional milestones payment receivable Additional Milestones Payment Receivable Additional Milestones Payment Receivable Exchange [Domain] Exchange [Domain] AGA Perf Employees 2019 / AGA Perf Management 2019 [Member] AGA Perf Employees 2019 / AGA Perf Management 2019 [Member] Related to stock plans. Suppliers (excluding payables related to capital expenditures) Current trade payables Executive Committee & Board members compensation Key management personnel compensation Disclosure of initial application of standards or interpretations[Table] Disclosure of initial application of standards or interpretations [table] Characteristics of defined benefit plans [axis] Characteristics of defined benefit plans [axis] Disclosure of defined benefit plans Disclosure of defined benefit plans [text block] Common shares Ordinary shares [member] Trade account receivables Current trade receivables Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [text block] AGA Bonus 2021-1 AGA Bonus 2021-1 [Member] AGA Bonus 2021-1 Income (loss) per share Disclosure of earnings per share [text block] Trade payables and others Payables and others Trade and other current payables Statutory tax rate Applicable tax rate Additions Increase Through Performance Obligation Being Satisfied, Contract Liabilities The increase in contract liabilities resulting from additions. Additional milestones payment, not eligible Additional Milestones Payment Receivable, Not Eligible Additional Milestones Payment Receivable, Not Eligible Development and regulatory milestones Development And Regulatory Milestones The development and regulatory milestones pursuant to the agreement. Local Phone Number Local Phone Number Change in working capital, adjusted Change In Working Capital, Adjusted Change In Working Capital, Adjusted Proceeds from the exercise / subscription of equity instruments Proceeds from issuing shares 2026 Not later than one year [member] AGA Management 2016-1  AGA Management 2016-1 [Member] This member stands for AGA Management 2016-1. Percent of employees using transport mobility Percent Of Employees Using Transport Mobility Percent Of Employees Using Transport Mobility AGA Perf Employees 2024-1 AGA Perf Employees 2024-1 [Member] AGA Perf Employees 2024-1 Deloitte & Associés Deloitte & Associés [Member] Deloitte & Associés Provision for defined benefit obligations Tax Effect Of Defined Benefit Obligations The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to defined benefit obligations. Number of specified targets Number Of Specified Targets Specified targets Fair value through profit or loss Financial liabilities at fair value through profit or loss, category [member] Total Auditor's remuneration Disclosure of financial assets [Line Items] Disclosure of financial assets [line items] Property and equipment Description of accounting policy for property, plant and equipment [text block] Proceeds from borrowings Proceeds from borrowings, classified as financing activities Entity Voluntary Filers Entity Voluntary Filers Unused tax losses subject to expiration Unused Tax Losses Subject To Expiration The amount of unused tax losses subject to expiration. Novo Nordisk A/S Novo Nordisk A/S [Member] This member stands for Novo Nordisk A/S. 16-24 years Actuarial Assumption Of Annual Turnover Rate By Age 16-24 Years The annual turnover rate for 16-24 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation. Repayments of borrowings and lease liabilities Repayments Of Borrowings And Lease Liabilities, Net Of Exchange Rate Variation, Classified As Financing Activities Repayments Of Borrowings And Lease Liabilities, Net Of Exchange Rate Variation, Classified As Financing Activities Entity Registrant Name Entity Registrant Name Basic income (loss) per share (in EUR per share) Basic earnings (loss) per share AGA Management 2016-2 AGA Management 2016-2 [Member] This member stands for AGA Management 2016-2. Revenue for the current financial year Recognition in P&L Decrease through performance obligation being satisfied, contract liabilities Foreign exchange (gains) losses on financial assets Adjustments for unrealised foreign exchange losses (gains) Deferred revenue - current and non-current portion, variance Adjustments for increase (decrease) in deferred income including contract liabilities Collaboration liabilities – current portion Collaboration Liabilities , Current The amount of current collaboration liabilities. Change in accrued interests on financial assets Adjustments for decrease (increase) in accrued income including contract assets Short-term investments, variation of fair value through the consolidated statement of income (loss) Short-term Investments, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss) The gains (losses) on current financial assets at fair value through profit or loss. Receivables Loans and receivables, category [member] Lease liabilities - IT security Lease Financing Obligations, IT Security [Member] Lease Financing Obligations, IT Security AGA Management 2024-1 AGA Management 2024-1 [Member] AGA Management 2024-1 Classes of intangible assets other than goodwill [domain] Classes of intangible assets other than goodwill [domain] Share-based compensation expense Adjustments for share-based payments Share issued, price per share (in EUR per share) Share Issued Price Per Share Per share or per unit amount of equity securities issued. AGA Bonus 2020 AGA Bonus 2020 [Member] AGA Bonus 2020 Types of financial assets [axis] Types of financial assets [axis] +50 years Actuarial Assumption Of Annual Turnover Rate By Age Over 50 Years The annual turnover rate for employees over 50 years old used as a significant actuarial assumption to determine the present value of a defined benefit obligation. Upfront payment Upfront Payment The upfront payment made to a counter party. Warrants Warrants [member] Number of voting rights held (in shares) Number Of Voting Rights Held Number Of Voting Rights Held Employee benefits Disclosure of employee benefits [text block] Financial transactions, related party transactions Financial Transactions, Related Party Transactions Financial Transactions, Related Party Transactions 2016 Preferred shares 2016 Preferred Shares [Member] 2016 Preferred Shares Shareholders' equity Equity [abstract] Entity Addresses [Line Items] Entity Addresses [Line Items] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of detailed information about financial instruments [abstract] Disclosure of detailed information about financial instruments [abstract] Prepayments made to suppliers Non-current prepayments Subclassifications of assets, liabilities and equities [abstract] Subclassifications of assets, liabilities and equities [abstract] Number of vesting kickers Number Of Vesting Kickers Number Of Vesting Kickers Disclosure of nature and extent of risks arising from financial instruments [abstract] Disclosure of nature and extent of risks arising from financial instruments [abstract] Repayment cost to AZ Decrease Through Repayments, Non Current Contract Liabilities Decrease Through Repayments, Non Current Contract Liabilities Research Tax Credit Income From Research Tax Credit The amount of income related to research tax credit. Collaboration liabilities – non-current portion Collaboration Liabilities, Non-Current The amount of non-current collaboration liabilities. Others Other Agreement [Member] This member stands for other agreement. Number of patients planned to be enrolled in medical study Number Of Patients Planned To Be Enrolled In Medical Study Number Of Patients Planned To Be Enrolled In Medical Study Change in fair value of short-term investments and non-current financial assets Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income AGA "Plan Epargne Entreprise" 2023 AGA "Plan Epargne Entreprise" 2023 AGA "Plan Epargne Entreprise" 2023 [Member] AGA "Plan Epargne Entreprise" 2023 Additions considerations Additions other than through business combinations, intangible assets other than goodwill Change in working capital, variance Increase (Decrease) In Working Capital, Before Adjustments Increase (Decrease) In Working Capital, Before Adjustments Disposal of current financial instruments and paid interests Disposal Of Current Financial Instruments And Paid Interests The cash inflow from the disposal of current financial instruments. ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Milestone payment received Revenue From Contracts With Customers, Milestone Payment Received Revenue From Contracts With Customers, Milestone Payment Received 2017 Preferred shares 2017 Preferred Shares [Member] 2017 Preferred Shares AGAP Employees 2017-1 AGAP Employees 2017 [Member] This member stands for AGAP Employees 2017. Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Agreement related to additional preclinical molecules with AstraZeneca Agreement Related To Additional Preclinical Molecules With AstraZeneca [Member] This member stands for agreement related to additional preclinical molecules with AstraZeneca. Restructuring provision Restructuring provision [member] Auditor Firm ID Auditor Firm ID Types of contracts [axis] Types of contracts [axis] Share premium Share premium [member] AGA Perf Management 2024-1 AGA Perf Management 2024-1 AGA Perf Management 2024-1 [Member] AGA Perf Management 2024-1 Disclosure of revenue from collaboration and licensing agreements Disclosure of disaggregation of revenue from contracts with customers [text block] Revenue from collaboration and licensing agreements, minimum accrual between attribution and definitive acquisition date Internal Conditions Performance, Revenue From Collaboration And Licensing Agreements, Minimum Accrual Between Attribution And Definitive Acquisition Date Internal Conditions Performance, Revenue From Collaboration And Licensing Agreements, Minimum Accrual Between Attribution And Definitive Acquisition Date Government financing for research expenditures Description of accounting policy for government grants [text block] BSAAR 2011 BSAAR 2011 [Member] This member stands for BSAAR 2011. Statistical Disclosure for Banks [Abstract] AGAP Employee 2020 / AGAP Management 2020 AGAP Employee 2020 / AGAP Management 2020 [Member] AGAP Employee 2020 / AGAP Management 2020 Equipment and office furniture Office equipment [member] Non-executives Non-executives [Member] This member stands for non-executives. Other comprehensive income Description Of Accounting Policy For Other Comprehensive Income [Policy Text Block] The description of the entity's accounting policy for other comprehensive income. Receipts from co-development agreement Receipts From Codevelopment Agreement The cash inflow from co-development agreement. Intangible assets Description of accounting policy for intangible assets other than goodwill [text block] Deferred revenue – non-current portion Non-current deferred income including non-current contract liabilities Deferred revenue – current portion Current deferred income including current contract liabilities Bpifrance Participations Bpifrance Participations [Member] Bpifrance Participations Other long term benefits, years of service, threshold two Other Long Term Benefits, Years Of Service, Threshold Two Other Long Term Benefits, Years Of Service, Threshold Two Property and equipment Property, plant and equipment including right-of-use assets at beginning of period Property, plant and equipment including right-of-use assets at end of period Property, plant and equipment including right-of-use assets Expiration period Unused Tax Losses Subject To Expiration, Period Unused Tax Losses Subject To Expiration, Period 5% retained - Tax credit refund, variance Adjustments For Increase (Decrease), Tax Credit Retentions, CIR Adjustments For Increase (Decrease), Tax Credit Retentions, CIR Disclosure of effect of changes in foreign exchange rates Disclosure of effect of changes in foreign exchange rates [text block] Top of range Top of range [member] Number of members of the supervisory board not appointed to the board of directors Number Of Members Of The Supervisory Board Not Appointed To The Board Of Directors Number Of Members Of The Supervisory Board Not Appointed To The Board Of Directors Share entitlement per free share (in shares) Share Entitlement Per Free Share Other Equity Instruments Granted The share entitlement per free share of other equity instruments granted. AGAP Management 2016-1  AGAP Management 2016-1 [Member] This member stands for AGAP Management 2016-1. Research and development expenses Research and development expense Agreements with Genzyme for NK Cell engages Agreements with Genzyme for NK Cell engages [Member] Agreements with Genzyme for NK Cell engages AGA AGA [Member] This member stands for AGA. 2029 Later than three years and not later than four years [member] Foreign exchange gains Net foreign exchange gain Allowance for seniority awards Seniority Awards [Member] This member stands for seniority awards. Actuarial gains and (losses) related to defined benefit obligations Actuarial (losses) gains on defined benefit obligations Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Technical installations and equipment Technical Installations And Equipment [Member] This member stands for technical installations and equipment. Diluted income (loss) per share from discontinued operations (in EUR per share) Diluted earnings (loss) per share from discontinued operations Number of collaboration contracts Number Of Collaboration Contracts Number Of Collaboration Contracts Rate of contributions Actuarial Assumption of Rate Of Contributions The percent of rate of contributions for actuarial assumptions. Property transaction (down-payment) Down-payment [Member] This member stands for down-payment. Advance received Revenue From Contracts With Customers, Advance Payment Received The amount of advance received by the company. Exercise and subscription of equity instruments (in shares) Exercise And Subscription Of Equity Instruments, In Shares The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments. Disclosure Of Detailed Information About Trade Payables And Others [Table] Disclosure Of Detailed Information About Trade Payables And Others [Table] Disclosure Of Detailed Information About Trade Payables And Others [Table] Borrowings by name Borrowings by name [domain] Defined benefit obligations Defined benefit obligation, at present value Defined benefit obligation, at present value Financial liabilities Financial Liabilities Trade Payables And Others The amount of financial liabilities, trade payables and others. Expected turnover (yearly basis) Expected Turnover Other Instruments Granted The expected turnover of other instruments granted. Payments for milestone Payments For Milestone Represents payments for milestone. Revenue from collaboration and licensing agreements Revenue from collaboration and licensing agreements Revenue from contracts with customers Number of options excercised for licenses Number of Options Excercised For Licenses Number of Options Excercised For Licenses Deferred tax liabilities, offset amount Deferred Tax Liabilities, Offset Amount Deferred Tax Liabilities, Offset Amount Disclosure of key management personnel compensation Disclosure Of Key Management Personnel Compensation [Table Text Block] The disclosure for key management personnel compensation. Non-Current Non-current contract liabilities [abstract] Number of subsidiaries Number Of Wholly Owned Subsidiaries Number Of Wholly Owned Subsidiaries 45-49 years Actuarial Assumption Of Annual Turnover Rate By Age 45-49 Years The annual turnover rate for 45-49 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation. Property, plant and equipment including right-of-use assets [axis] Property, plant and equipment including right-of-use assets [axis] Income taxes refund, classified as operating activities Income taxes paid (refund), classified as operating activities Other comprehensive income (loss) Other comprehensive income Classes of liabilities [axis] Classes of liabilities [axis] Counterparties Counterparties [domain] IPH5201 agreement, with AstraZeneca of which IPH5201 agreement - AstraZeneca Agreement Related To IPH5201 With AstraZeneca [Member] This member stands for Agreement related to IPH5201 with AstraZeneca. AGAP Perf Employees 2018-1 AGAP Perf Employees 2018-1 [Member] Related to the plan. CIR retention, maturity CIR Retention, Maturity CIR Retention, Maturity Number of preclinical molecules Number Of Preclinical Molecules Number Of Preclinical Molecules Non-current financial assets, disposals Decrease Through Derecognition Non-current Financial Assets The decrease in non-current financial assets resulting from derecognition. Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Depreciation and amortization, net Adjustments for depreciation and amortisation expense 5% retained - Tax credit refund Tax Credit Retentions, CIR Tax Credit Retentions, CIR AGA Bonus 2019-1 AGA Bonus 2019-1 [Member] Related to AGA bonus 2019-1. Title of 12(b) Security Title of 12(b) Security Increase capital, net Issue of equity Undiscounted cash flows Bank borrowings, undiscounted cash flows Non-current financial assets, acquisitions Non-current Financial Assets, Acquisitions The increase in non-current financial assets resulting from origination or purchase. Collection Cash advances and loans from related parties Rate of wages costs Actuarial Assumption of Employee Contributions The amount of rate of wages costs in actuarial assumptions. Disclosure of variance of deferred revenue Disclosure Of Variance Of Deferred Revenue [Table Text Block] The disclosure of variance of deferred revenue. Unrealized losses on financial assets Unrealized Losses On Financial Assets The amount of unrealized losses on financial assets. Total cash, cash equivalents and financial assets Cash, cash equivalents and financial assets Total Cash, Cash Equivalents And Financial Assets The amount of cash, cash equivalents and financial assets. Collaboration liabilities - current and non-current portion, variance Adjustments For Increase (Decrease) In Collaboration Liabilities Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)] AGAP Management 2016-2 AGAP Management 2016-2 [Member] This member stands for AGAP Management 2016-2. Critical accounting estimates and assumptions Description Of Accounting Policy For Accounting Estimates And Assumptions [Policy Text Block] The description of the entity's accounting policy for accounting estimates and assumptions. Trade receivables and others - non-current Receivables and others - non-current Trade and other non-current receivables Disclosure of closing balance of share-based payment arrangements Disclosure Of Closing Balance Of Share-based Payment Arrangements [Table Text Block] The entire disclosure for closing balance of of share-based payment arrangements. Attribution of expenses by nature to their function Attribution of expenses by nature to their function [domain] Net income (loss) before tax Accounting profit AGAP Employee 2021 / AGAP Management 2021 AGAP Employee 2021 / AGAP Management 2021 [Member] AGAP Employee 2021 / AGAP Management 2021 Statement of compliance Description Of Statement Of Compliance [Policy Text Block] The description of statement of compliance. Disclosure Of Detailed Information About Trade Payables And Others [Line Items] Disclosure Of Detailed Information About Trade Payables And Others [Line Items] Disclosure Of Detailed Information About Trade Payables And Others [Line Items] Depreciation Depreciation, property, plant and equipment including right-of-use assets Share capital and share based payments Disclosure of issued capital [text block] Property, plant and equipment including right-of-use assets [domain] Property, plant and equipment including right-of-use assets [domain] Revenue from favorable cumulative adjustment Revenue From Contracts With Customers, Favorable Cumulative Adjustment The amount of favorable cumulative adjustment to revenue. Repayment of borrowings Repayments of borrowings, classified as financing activities Auditors Remuneration [Line Items] Auditors Remuneration [Line Items] Auditors Remuneration Borrowings by name [axis] Borrowings by name [axis] Short-term investments Short-term investments Current financial assets Trade payables and others Disclosure of trade and other payables [text block] Other free shares Other Free Shares [Member] Other Free Shares Number of exclusive options granted Number Of Exclusive Options Granted Number Of Exclusive Options Granted PGE loan agreement, Societe Generale and BNP Paribas PGE Loan Agreement, Societe Generale And BNP Paribas [Member] PGE Loan Agreement, Societe Generale And BNP Paribas Disclosure of changes in share capital Disclosure of classes of share capital [text block] Travel expenses and meeting attendance Travel expense Total, disposals Decrease Through Derecognition Short-term Investment And Non-current Financial Assets The decrease in short-term investment and non-current financial assets resulting from derecognition. Disclosure of expenses by nature Disclosure of expenses by nature [text block] Number of cohorts of the trial that did not meet primary endpoints Number Of Cohorts Of The Trial That Did Not Meet Primary Endpoints Number Of Cohorts Of The Trial That Did Not Meet Primary Endpoints Net income (loss) Retained earnings, profit (loss) for reporting period [member] Commitments, contingencies and litigations Disclosure of commitments and contingent liabilities [text block] Financial instruments recognized in the statement of financial position and related effect on the income statement Disclosure of financial instruments [text block] Maximum potential regulatory milestones and single-digit tiered royalties on sale of products Maximum Potential Regulatory Milestones And Single-digit Tiered Royalties On Sale Of Products The maximum amount of potential regulatory milestones and single-digit tiered royalties on sale of products. Disclosure of detailed information about property, plant and equipment Disclosure of detailed information about property, plant and equipment [text block] Purchased licenses Licences [member] Borrowings, interest rate Borrowings, interest rate Net cash generated from / (used in) investing activities Cash flows from (used in) investing activities Payments Cash advances and loans made to related parties Percentage of premium increased Percentage Of Premium Increased The percentage of premium increased. Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Non-current financial assets Beginning balance, non-current financial assets Ending balance, non-current financial assets Non-current financial assets Personnel expenses Employee benefits expense Commitments, Contingencies And Litigations [Abstract] Commitments, Contingencies And Litigations [Abstract] Commitments, Contingencies And Litigations Depreciation Amortisation, intangible assets other than goodwill AGAP 2019 Employees 2019 AGAP 2019 Employees 2019 [Member] Related to the plan. Financial instruments Description of accounting policy for financial instruments [text block] Change in working capital Change in working capital, variance Increase (decrease) in working capital Total current assets Current assets Stock Options 2024-1 Stock-option 2024 Stock Options 2024 [Member] Stock Options 2024 AGA Perf Employees 2021-1 AGA Perf Employees 2021-1 [Member] AGA Perf Employees 2021-1 Collaboration liabilities Collaboration Liabilities [Member] This member stands for collaboration liabilities. Disclosure of operating segments [Table] Disclosure of operating segments [table] Retained earnings Retained earnings, excluding profit (loss) for reporting period [member] Members of the Executive Board, Supervisory Board and Leadership Team Members of the Executive Board, Supervisory Board and Leadership Team [Member] Members of the Executive Board, Supervisory Board and Leadership Team Operating cash flow before change in working capital Cash flows from (used in) operations before changes in working capital Employees born before 1 January 1968 Employees Born Before 1 January 1968 [Member] Employees Born Before 1 January 1968 Defined contribution plan, contribution percentage Defined Contribution Plan Contribution Percentage The contribution percentage pursuant to the defined contribution plan. Trade and other payables [abstract] Installations Installations [Member] This member stands for installations. Percentage of payments in US dollars Percentage Of Payments In US Dollars The percentage of payments in US dollars. Disclosure of transactions between related parties [Table] Disclosure of transactions between related parties [table] Non-current assets held for sale and discontinued operations Description of accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations [text block] Change in fair value of financial assets Adjustments for fair value losses (gains) AGAP 2019 Management 2019 AGAP 2019 Management 2019 [Member] Related to the plan. Performance conditions threshold Other Equity Instruments, Performance Conditions Threshold Other Equity Instruments, Performance Conditions Threshold Profit (loss) [abstract] Profit (loss) [abstract] Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] Disposal of other assets Proceeds from sales of other long-term assets, classified as investing activities Par value per share (in EUR per share) Nominal value (in EUR per share) Par value per share Property and equipment Disclosure of property, plant and equipment [text block] Post-employment benefit expense, defined contribution plans Post-employment benefit expense, defined contribution plans Amendment Flag Amendment Flag Withholding tax - CIR reclassified under non-current financial assets Withholding Tax - CIR Reclassified Under Non-Current Financial Assets Withholding Tax - CIR Reclassified Under Non-Current Financial Assets Components of equity Components of equity [domain] Restructuring costs Expense of restructuring activities Statement Line Items [Line Items] Disclosure of operating segments [line items] Sanofi services Sanofi Services [Member] Sanofi Services Employee benefits Description of accounting policy for employee benefits [text block] BSA 2015-2 BSA 2015-2 [Member] This member stands for BSA 2015-2. Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Employees born after 1 January 1968 Employees Born After 1 January 1968 [Member] Employees Born After 1 January 1968 Range [domain] Range [domain] Disposal of property and equipment (scrapping) Adjustments for gain (loss) on disposals, property, plant and equipment Trade payables and others (excluding payables related to capital expenditures), variance Adjustments for increase (decrease) in trade and other payables AGA Perf Employees 2018 AGA Perf Employees 2018 [Member] This member stands for AGA Perf Employees 2018. Liabilities Amounts payable, related party transactions Increase (decrease) due to changes in accounting policy required by IFRSs Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member] Document Financial Statement Restatement Recovery Analysis [Flag] Document Financial Statement Restatement Recovery Analysis [Flag] Financial liabilities – non-current portion Non-current financial liabilities Impairment loss recognised in profit or loss, trade receivables Impairment loss recognised in profit or loss, trade receivables AGA New Members 2023-1 AGA Bonus 2023-1 [Member] AGA Bonus 2023-1 Collaboration Liabilities, Roll Forward [Abstract] Collaboration Liabilities, Roll Forward [Abstract] Collaboration Liabilities, Roll Forward Government financing for research expenditures Government financing for research expenditures Government Financing For Research Expenditures The amount of income recognised in relation to government financing for research expenditures. Address Type [Domain] Address Type [Domain] Notional amount Notional amount Fx impact Foreign Exchange Gain (Loss), Contract Liabilities Foreign Exchange Gain (Loss), Contract Liabilities Invoicing of research and development costs (IPH5201) Invoicing Research And Development Costs IPH5201 [Member] Invoicing Research And Development Costs IPH5201 Disclosure of actuarial assumptions for defined benefit plans Disclosure Of Actuarial Assumptions For Defined Benefit Plans [Text Block] The disclosure of actuarial assumptions for defined benefit plans. AGA New Members 2023-1 AGA New Members 2023-1 Management AGA New Members 2023-1 Management [Member] AGA New Members 2023-1 Management 30-34 years Actuarial Assumption Of Annual Turnover Rate By Age 30-34 Years The annual turnover rate for 30-34 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation. AGAP 2016-2 AGAP 2016-2 [Member] This member stands for AGAP 2016-2. Diluted income (loss) per share (in EUR per share) Diluted earnings (loss) per share Maturity [domain] Maturity [domain] Capital Description of accounting policy for issued capital [text block] Categories of financial liabilities [axis] Categories of financial liabilities [axis] Percentge of annual variable compensation Percentage Of Annual Variable Compensation The percentage of annual variable compensation. Disclosure of terms and conditions of share-based payment arrangement [Table] Disclosure of terms and conditions of share-based payment arrangement [table] Effective tax rate Average effective tax rate 25-29 years Actuarial Assumption Of Annual Turnover Rate By Age 25-29 Years The annual turnover rate for 25-29 years old employees used as a significant actuarial assumption to determine the present value of a defined benefit obligation. Summary of income (loss) per share Earnings per share [text block] BSA 2015-1 BSA 2015-1 [Member] This member stands for BSA 2015-1. Intangible assets other than goodwill [abstract] Intangible assets other than goodwill [abstract] Counterparty Name [Axis] Counterparty Name [Axis] Non-scientific advisory and consulting Non-scientific Advisory And Consulting The amount of non-scientific advisory and consulting. Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Acquisition of intangible assets Purchase of intangible assets Purchase of intangible assets, classified as investing activities AGA Perf Employees 2019 AGA Perf Employees 2019 [Member] Related to the plan. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code